The Game-Changing Partnership that Could Revolutionize mRNA Therapeutics
The joint venture between Wacker Biotech and RNAV8 Bio is advancing mRNA-based therapies. Focus is on optimizing mRNA untranslated regions (UTRs) to enhance drug stability and efficacy. Wacker Biotech's mRNA…
Eli Lilly’s Bold Move: A Lifeline for Gene Therapy’s Bleak Horizon?
Sangamo Therapeutics and Eli Lilly inked an $18 million deal to advance treatments for central nervous system diseases using Sangamo's STAC-BBB technology. The STAC-BBB capsid can effectively penetrate the blood-brain…
Trump’s Unexpected Tariff Twist Leaves Pharma Breathless but Buoyant
The pharmaceutical and biotech sectors exhibited resilience amid broad economic turmoil, largely unaffected by sweeping tariffs. Companies like Catalyst Pharmaceuticals and Veeva Systems experienced only minor stock declines, while Amgen…
Seattle’s Power Players: Meet the Innovators Reshaping the Future
Jill Angelo transitions from Unified Women’s Healthcare, leaving a legacy in menopause health awareness and telehealth services with Gennev. Aurion Biotech advances in cell therapies for eye diseases, bolstered by…
A Bold Move Against Epilepsy: How Neurona Therapeutics Plans to Defy the Odds
Neurona Therapeutics is advancing allogeneic cell therapy for drug-resistant mesial temporal lobe epilepsy (MTLE) with its promising NRTX-1001 therapy. Supported by a $102 million financing round, Neurona is navigating the…
Can Neurona’s Revolutionary Cell Therapy Transform the Future of Epilepsy Treatment?
Neurona Therapeutics has secured $102 million to advance its innovative cell therapy for epilepsy into phase 3 testing. The therapy, NRTX-1001, targets drug-resistant mesial temporal lobe epilepsy using GABAergic interneurons…
The Storm in Biotech: What’s Causing High-Flying Stocks to Plummet?
Early-stage biotech companies, including Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics, faced significant stock declines, with Biohaven down 35.3% in March's closing quarter. Biotech firms, often investment-heavy and loss-making, are struggling…
Unraveling the Turmoil: Why Biotech Stocks Plummeted and What Investors Should Know
March was a challenging month for early-stage biotech stocks, with notable companies like Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics experiencing significant share price declines. Biohaven's drug candidate BHV-7000 underperformed in…
The Roller Coaster of Biotech Stocks: A March to Forget or a Prelude to Innovation?
The biotech sector faced significant challenges, causing stocks like Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics to plummet. Biohaven's stock decreased by 35.3% due to disappointing results from its bipolar disorder…
Revolutionary Partnership Propels Biopharmaceutical Innovations from Lab Bench to Clinical Trials
ERBC and Menarini Biotech have formed a strategic alliance to revolutionize early-stage biopharmaceutical development. This partnership bridges the gap between scientific research and clinical trials through combined expertise in non-clinical…